NYSE - Nasdaq Real Time Price • USD
Teva Pharmaceutical Industries Limited (TEVA)
As of 1:02 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 12 | 13 |
| Avg. Estimate | 0.51 | 0.58 | 2.41 | 2.64 |
| Low Estimate | 0.47 | 0.54 | 2.3 | 2.54 |
| High Estimate | 0.54 | 0.61 | 2.5 | 2.8 |
| Year Ago EPS | 0.4 | 0.56 | 2.56 | 2.41 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 12 | 12 |
| Avg. Estimate | 3.73B | 4B | 15.87B | 16.34B |
| Low Estimate | 3.63B | 3.95B | 15.57B | 15.84B |
| High Estimate | 3.82B | 4.08B | 16.04B | 16.68B |
| Year Ago Sales | 3.63B | -- | 15.85B | 15.87B |
| Sales Growth (year/est) | 2.80% | -- | 0.10% | 3.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.56 | 0.52 | 0.61 | 0.77 |
| EPS Actual | 0.4 | 0.56 | 0.6 | 1 |
| Difference | -0.16 | 0.04 | -0.01 | 0.23 |
| Surprise % | -28.60% | 7.70% | -1.60% | 29.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.51 | 0.58 | 2.41 | 2.64 |
| 7 Days Ago | 0.52 | 0.58 | 2.41 | 2.64 |
| 30 Days Ago | 0.52 | 0.58 | 2.4 | 2.63 |
| 60 Days Ago | 0.52 | 0.58 | 2.41 | 2.64 |
| 90 Days Ago | 0.5 | 0.58 | 2.42 | 2.59 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | TEVA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 27.50% | -- | -- | 1.50% |
| Next Qtr. | 3.60% | -- | -- | 11.40% |
| Current Year | -5.90% | -- | -- | 5.20% |
| Next Year | 9.50% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 1.60% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 1.90% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | JP Morgan: Underweight to Neutral | 3/8/2024 |
| Upgrade | Piper Sandler: Neutral to Overweight | 2/12/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 2/5/2024 |
| Maintains | Barclays: Overweight to Overweight | 2/5/2024 |
| Maintains | Barclays: Overweight to Overweight | 1/29/2024 |
| Upgrade | Jefferies: Hold to Buy | 1/23/2024 |
Related Tickers
VTRS Viatris Inc.
11.47
-0.74%
ALVO Alvotech
13.67
+0.96%
ELAN Elanco Animal Health Incorporated
12.87
-3.34%
BHC Bausch Health Companies Inc.
8.62
+0.64%
TLRY Tilray Brands, Inc.
1.7650
-4.08%
ACB Aurora Cannabis Inc.
6.75
-6.25%
PRGO Perrigo Company plc
31.64
+1.31%
DVAX Dynavax Technologies Corporation
11.29
-1.18%
ESPR Esperion Therapeutics, Inc.
1.9900
-6.57%
CGC Canopy Growth Corporation
8.90
-0.84%